These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers. Qing T; Wang X; Jun T; Ding L; Pusztai L; Huang KL Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572800 [TBL] [Abstract][Full Text] [Related]
27. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients. Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282 [TBL] [Abstract][Full Text] [Related]
29. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111 [TBL] [Abstract][Full Text] [Related]
30. Genetic landscape of homologous recombination repair and practical outcomes of PARPi therapy in ovarian cancer management. Chen M; Lei N; Guo R; Han L; Zhao Q; Zhao Y; Qiu L; Wu F; Jiang S; Tong N; Wang K; Li S; Chang L Ther Adv Med Oncol; 2024; 16():17588359241271845. PubMed ID: 39246808 [TBL] [Abstract][Full Text] [Related]
31. The Features of Luo Y; Wu H; Huang Q; Rao H; Yu Z; Zhong Z Int J Gen Med; 2022; 15():2773-2786. PubMed ID: 35300142 [TBL] [Abstract][Full Text] [Related]
32. A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing. Ellison G; Huang S; Carr H; Wallace A; Ahdesmaki M; Bhaskar S; Mills J BMC Clin Pathol; 2015; 15():5. PubMed ID: 25859162 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Ion Torrent PGM sequencing workflow for the routine rapid detection of BRCA1 and BRCA2 germline mutations. Zanella I; Merola F; Biasiotto G; Archetti S; Spinelli E; Di Lorenzo D Exp Mol Pathol; 2017 Apr; 102(2):314-320. PubMed ID: 28263838 [TBL] [Abstract][Full Text] [Related]
35. RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis. Tsantikidi A; Papazisis K; Floros T; Gazouli M; Papadopoulou E; Tsaousis G; Nasioulas G; Mester A; Milan KP; Gozman B; Afrasanie V; Stanculeanu DL; Trifanescu O; Pescaru F; Militaru C; Papadimitriou C Oncol Lett; 2023 Nov; 26(5):480. PubMed ID: 37809048 [TBL] [Abstract][Full Text] [Related]
36. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469 [TBL] [Abstract][Full Text] [Related]
37. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related]
38. Detection of Ratajska M; Koczkowska M; Żuk M; Gorczyński A; Kuźniacka A; Stukan M; Biernat W; Limon J; Wasąg B Oncotarget; 2017 Nov; 8(60):101325-101332. PubMed ID: 29254167 [TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893 [TBL] [Abstract][Full Text] [Related]
40. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations]. Vošmiková H; Ryška A; Sieglová K; Laco J Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]